Julia Suchomel

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard A. Burris et al. · Clinical Cancer Research · 2019 · 281 citations · Full text

Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3

Zhihong Li, Xianghong Wang, John Eksterowicz et al. · Journal of Medicinal Chemistry · 2014 · 70 citations · Full text

Molecular Biology, Structural Optimization, Activated State +22

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

Benjamin Wu, Nitzan Sternheim, Priya Agarwal et al. · Clinical and Translational Science · 2021 · 51 citations · Full text

Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors

Youngsook Shin, Julia Suchomel, Mario Cardozo et al. · Journal of Medicinal Chemistry · 2015 · 34 citations · Full text

Pharmaceutical Science, Immunology, Cellular Pharmacology +24

Synthesis and SAR study of potent and selective PI3Kδ inhibitors

Minna Bui, Xiaolin Hao, Youngsook Shin et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 23 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Selective Pi3kδ Inhibitors +11